Ford Ian, Murray Heather, Packard Chris J, Shepherd James, Macfarlane Peter W, Cobbe Stuart M
Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom.
N Engl J Med. 2007 Oct 11;357(15):1477-86. doi: 10.1056/NEJMoa065994.
The West of Scotland Coronary Prevention Study was a randomized clinical trial comparing pravastatin with placebo in men with hypercholesterolemia who did not have a history of myocardial infarction, with an average follow-up of approximately 5 years. The combined outcome of death from definite coronary heart disease or definite nonfatal myocardial infarction was reduced from 7.9 to 5.5% (P<0.001) in the treatment group. Extended follow-up data were obtained for approximately 10 years after completion of the trial.
For the survivors of the trial, all deaths, hospitalizations and deaths due to coronary events and stroke, and incident cancers and deaths from cancer were tracked with the use of a national computerized record-linkage system. The results were analyzed with time-to-event analyses and use of Cox proportional-hazards models.
Five years after the trial ended, 38.7% of the original statin group and 35.2% of the original placebo group were being treated with a statin. In the period approximately 10 years after completion of the trial, the risk of death from coronary heart disease or nonfatal myocardial infarction was 10.3% in the placebo group and 8.6% in the pravastatin group (P=0.02); over the entire follow-up period, the rate was 15.5% in the placebo group and 11.8% in the pravastatin group (P<0.001). Similar percentage reductions were seen in the combined rate of death from coronary heart disease and hospitalization for coronary events for both periods. The rate of death from cardiovascular causes was reduced (P=0.01), as was the rate of death from any cause (P=0.03), over the entire follow-up period. There were no excess deaths from noncardiovascular causes or excess fatal or incident cancers.
In this analysis, 5 years of treatment with pravastatin was associated with a significant reduction in coronary events for a subsequent 10 years in men with hypercholesterolemia who did not have a history of myocardial infarction.
苏格兰西部冠心病预防研究是一项随机临床试验,比较了普伐他汀与安慰剂对无心肌梗死病史的高胆固醇血症男性的疗效,平均随访约5年。治疗组中确诊冠心病死亡或确诊非致死性心肌梗死的联合结局从7.9%降至5.5%(P<0.001)。试验结束后获得了约10年的延长随访数据。
对于试验幸存者,使用国家计算机化记录链接系统追踪所有死亡、因冠心病事件和中风住院及死亡情况,以及新发癌症和癌症死亡情况。结果采用事件发生时间分析和Cox比例风险模型进行分析。
试验结束5年后,原他汀组38.7%的患者和原安慰剂组35.2%的患者正在接受他汀治疗。在试验完成后约10年期间,安慰剂组冠心病死亡或非致死性心肌梗死风险为10.3%,普伐他汀组为8.6%(P=0.02);在整个随访期内,安慰剂组这一比例为15.5%,普伐他汀组为11.8%(P<0.001)。两个时期冠心病死亡和冠心病事件住院联合发生率的降低百分比相似。在整个随访期内,心血管病因死亡率降低(P=0.01),任何原因死亡率也降低(P=0.03)。无因非心血管病因导致的额外死亡或额外致命或新发癌症。
在此分析中,对于无心肌梗死病史的高胆固醇血症男性,5年普伐他汀治疗与随后10年冠心病事件显著减少相关。